Osteogenesis imperfecta is a genetic disorder of increased bone fragility, low bone mass,
and other connective-tissue manifestations. The most frequently used classification outlines …

The major clinical feature that defines osteogenesis imperfecta (OI) is bone fragility. We
begin the chapter with a discussion of the history, prevalence, and classification of OI. After a …

Severe osteogenesis imperfecta (OI) is a hereditary disorder characterized by increased
bone fragility and progressive bone deformity. Cyclical pamidronate infusions improve …

Aim: To find an effective symptomatic treatment for osteogenesis imperfecta (OI). Methods: In
a prospective observational study disodium pamidronate (APD) was given as monthly …

Osteogenesis imperfecta (OI) is the most common bone genetic disorder and it is
characterized by bone brittleness and various degrees of growth disorder. Clinical severity …

Background Non-randomised studies have suggested beneficial effects of bisphosphonates
in osteogenesis imperfecta. We assessed the effects of oral olpadronate in children with this …

Objectives. Treatment with pamidronate improves the clinical course in children with
osteogenesis imperfecta (OI), but theoretically might affect longitudinal growth. In this study …

Objective Osteopenia/osteoporosis is being increasingly reported as a complication of many
chronic diseases, even in children. In this preliminary study, we evaluated the effect of an …

Osteogenesis imperfecta (OI), a heritable disease caused by molecular defects in type I
collagen, is characterized by skeletal deformities and brittle bones. The heterozygous and …

A 2‐year prospective, partially randomized open‐label trial comparing oral alendronate with
intravenous pamidronate therapy in children with OI showed equivalence in increasing total …